Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Astellas’ HIF-PH Inhibitor, Trintellix, Venclexta, and Many More OK’ed for Listing on Nov. 19
November 13, 2019
- Keytruda to Get 17.5% Price Cut in February
November 13, 2019
- Bayer’s Xtandi Rival, AbbVie’s JAK Inhibitor Up for MHLW Panel Review on Nov. 25; 2 More Indications for Keytruda Also on Agenda
November 12, 2019
- Public-Private Confab Set for November 18; 2020 Reform, PMD Law Up for Discussion
November 12, 2019
- MHLW Sees No Major Problem with Current Rules for Low-Price Products, Chuikyo Questions Price Negotiation Process
November 12, 2019
- Keytruda Faces Price Slash on Better-than-Expected Sales
November 12, 2019
- PMDA Reviewing Safety Risks for Tecentriq, Tagrisso and More
November 12, 2019
- Chuikyo Positive about Changing Rules to Set Sales Thresholds after Market Expansion Re-Pricing Applied
November 11, 2019
- Japan to Use September 2019 Market Price Data for 2020 Revisions, April 2018 NHI Prices as Baseline
November 11, 2019
- LDP Lawmakers to Launch Group to Reinstate HPV Vaccine Recommendation
November 11, 2019
- Opposition Party Set to Compile HPV Vaccine Proposal by Year-End
November 8, 2019
- Substantive Diet Discussions Get Underway for PMD Law Amendment
November 7, 2019
- Zolgensma Not on Roster for Nov. 13 MHLW Panel Review
November 7, 2019
- Japan Industry Asks for AMED Funding of 50 Billion Yen to Build Big Data Platform
November 6, 2019
- Aso, CEFP Members Talked about Aducanumab at Oct. 28 Meeting, Minutes Reveal
November 6, 2019
- MOF Frets Financial Impact of Pricey Meds for Big Patient Populations, Cites Xolair’s Use in Pollen Allergy
November 5, 2019
- Australia Adds Japan to List of Countries Eligible for Expedited Review of New Drugs
November 5, 2019
- Key Japan Panel OKs Xolair as 1st Antibody Drug for Pollen Allergy
November 1, 2019
- MHLW Orders Label Revision for ADHD Treatment Concerta Based on New Distribution Control Policy
October 31, 2019
- Healthcare Providers Fret over Safety of Alternatives to Ranitidine amid Recalls
October 30, 2019
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…